Samsung Bioepis recently released its Tenth Edition Biosimilar Market Report for the Third Quarter of 2025, shedding light on the dynamic and rapidly evolving biosimilar landscape in the United States. With a significant increase in approvals and product launches since the initial report in Q2 2023, the market is experiencing accelerated growth and complexity. Thomas Newcomer, VP of U.S. commercial operations at Samsung Bioepis, emphasizes the importance of providing clear, data-driven insights to help stakeholders navigate this changing environment. The report delves into key topics such as the impact of the MFN policy on biosimilar pricing, the significance of quality manufacturing for successful market integration, and the role of transparency in enhancing market evolution. By offering objective analysis and valuable insights, Samsung Bioepis aims to facilitate a deeper understanding of the U.S. biosimilar market dynamics and trends.
Read more from drugstorenews.com